Valuation Abbott Laboratories Wiener Boerse
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 91.10 EUR | +2.36% |
|
+2.49% | -16.01% |
| 07:42am | Abivax strengthens its commercial leadership team |  |
| 07-23 | Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 175,488 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -19.45% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 198,869 | 191,232 | 187,428 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -10.53% | -3.84% | -1.99% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 28.6x | 22.2x | 19.9x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.86x | 3.45x | 3.25x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.51x | 0.8x | 1.7x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.49x | 3.21x | 3.01x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.95x | 3.5x | 3.21x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.4x | 13.2x | 11.9x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17x | 14.7x | 13.1x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.1x | 20.4x | 18.4x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.99% | 4.89% | 5.45% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.587 | 2.721 | 2.858 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.57% | 2.7% | 2.84% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.527 | 4.536 | 5.066 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.3% | 60% | 56.4% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,286 | 54,629 | 58,377 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,939 | 14,441 | 15,804 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,715 | 13,022 | 14,321 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,320 | 7,944 | 8,824 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,381 | 15,744 | 11,941 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 100.75 | 100.75 | 100.75 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,741,813 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.61x | 3.27x | 11.49x | 3.63% | 105B | |
| 16.97x | 0.19x | 11.99x | 0.78% | 59.35B | |
| 31.34x | 7.61x | 19.89x | 1.28% | 50.71B | |
| 38.12x | 3.05x | 10.41x | 2.52% | 42.15B | |
| 36.08x | 1.33x | 11.7x | 0.27% | 31.82B | |
| 28.79x | 5.12x | 16.34x | -.--% | 27.2B | |
| 41.9x | 7.46x | 26.85x | 0.25% | 25.11B | |
| 23.19x | 3.39x | 12.2x | 1.25% | 20.53B | |
| 19.04x | 2.63x | 10.25x | 1.65% | 19.42B | |
| Average | 28.23x | 3.78x | 14.57x | 1.29% | 42.36B | |
| Weighted average by Cap. | 26.19x | 3.56x | 13.92x | 1.76% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
